This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KIN Kindred Biosciences (KIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Kindred Biosciences Stock (NASDAQ:KIN) 30 days 90 days 365 days Advanced Chart Get Kindred Biosciences alerts:Sign Up Key Stats Today's Range$9.24▼$9.2650-Day Range$9.08▼$9.2552-Week Range$3.46▼$9.28Volume178,496 shsAverage Volume840,890 shsMarket Capitalization$420.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Read More… Receive KIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KIN Stock News HeadlinesWhy Silicon Valley falls prey to ‘charisma distortion,’ according to investor and Google X founding member Tom ChiAugust 19, 2024 | msn.comWillow Smith announces the new release date of her first book “Black Shields Maiden”April 23, 2024 | msn.comThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for it: "Elon Time." But this time... it’s different. A fleet of autonomous robotaxis is scheduled to be unleashed on the streets of Austin, Texas, this July.June 16, 2025 | Brownstone Research (Ad)Tory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire PoliceMarch 22, 2024 | mirror.co.ukKindred Hospital East GreensboroFebruary 23, 2024 | health.usnews.comJapan's Sony terminates $10 bln Zee India mergerJanuary 22, 2024 | reuters.comEuropean Shares Edge Higher With ECB Meeting In The SpotlightJanuary 22, 2024 | markets.businessinsider.comEarnings Optimism May Contribute To Continued Strength On Wall StreetJanuary 22, 2024 | markets.businessinsider.comSee More Headlines KIN Stock Analysis - Frequently Asked Questions How were Kindred Biosciences' earnings last quarter? Kindred Biosciences, Inc. (NASDAQ:KIN) issued its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to the consensus estimate of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%. What other stocks do shareholders of Kindred Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol-Myers Squibb (BMY) and Meta Platforms (META). Company Calendar Last Earnings8/05/2021Today6/15/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:KIN CIK1561743 Webkindredbio.com Phone(650) 701-7901FaxN/AEmployees63Year Founded2013Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.80 million Net Margins-529.26% Pretax MarginN/A Return on Equity-54.19% Return on Assets-39.76% Debt Debt-to-Equity Ratio0.19 Current Ratio7.02 Quick Ratio7.02 Sales & Book Value Annual Sales$42.16 million Price / Sales9.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book5.29Miscellaneous Outstanding Shares45,462,000Free FloatN/AMarket Cap$420.52 million OptionableOptionable Beta1.30 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:KIN) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kindred Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kindred Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
